Top

Indian Journal of Otolaryngology and Head & Neck Surgery

Published in:

12-09-2023 | Rhinosinusitis | Original Article

Emerging Therapies in the Medical Management of Allergic Fungal Rhinosinusitis

Authors: Osama A. Marglani, Rehab F. Simsim

Published in: Indian Journal of Otolaryngology and Head & Neck Surgery | Issue 1/2024

Abstract

A non-invasive type of chronic sinusitis named allergic fungal rhinosinusitis (AFRS), which is a variant of allergic bronchopulmonary aspergillosis with nasal obstruction, was first described in 1976. The goal of this article was to provide an overview of various treatment approaches and how they can be used to control AFRS. Since this is an inflammatory disease rather than an invasive fungal infection, the treatment tries to modulate inflammation and reduce disease burden. A comprehensive treatment strategy must incorporate medicinal, surgical, biological, and immunological techniques. Owing to the chronic nature of allergic fungal rhinosinusitis and its high propensity for flare-ups and recurrence, multiple procedures are frequently required. The most likely method of establishing a long-term disease control for AFRS is a comprehensive management strategy that integrates medical, surgical, and immunological care. However, there are still disagreements regarding the exact combinations. In this review, we have mentioned different modalities in the management of AFRS, such as monoclonal antibodies, probiotic Manuka honey, and aPDT among others, some of which are promising but require further research.

AlAhmari AA (2021) Allergic fungal rhinosinusitis in Saudi Arabia: a review of recent literature. Cureus 13:1–8

Marglani O (2014) Update in the management of allergic fungal sinusitis. Saudi Med J 35:791–795PubMed

Ponikau JU, Sherris DA, Kern EB, Homburger HA, Frigas E, Gaffey TA et al (1999) The diagnosis and incidence of allergic fungal sinusitis. Mayo Clin Proc 74:877–884CrossRefPubMed

Kuhn FA, Swain R (2003) Allergic fungal sinusitis: diagnosis and treatment. Curr Opin Otolaryngol Head Neck Surg 11:1–5CrossRefPubMed

Medikeri G, Javer A (2020) Optimal management of allergic fungal rhinosinusitis. J Asthma Allergy 13:323–332CrossRefPubMedPubMedCentral

Thrasher RD, Kingdom TT (2003) Fungal infections of the head and neck: an update. Otolaryngol Clin N Am 36:577–594CrossRef

Marglani OA, Kamel R, Herzallah IR, Shaikh AM (2017) Contralateral outcome in unilateral allergic fungal rhinosinusitis: impact on patient management and counseling. Pan Arab J Rhinol 7:1

Bent J, Kuhn FA (1994) Diagnosis of allergic fungal sinusitis. Otolaryngol Head Neck Surg 111:580–588CrossRefPubMed

Kupferberg SB, Bent JP, Kuhn FA (1997) Prognosis for allergic fungal sinusitis. Otolaryngol Head Neck Surg 117:35–41CrossRefPubMed

10.

Kuhn FA, Javer AR (2000) Allergic fungal rhinosinusitis: perioperative management, prevention of recurrence, and role of steroids and antifungal agents. Otolaryngol Clin N Am 33:161–171CrossRef

11.

Khosla AJ, Pernas FG, Maeso PA (2013) Meta-analysis and literature review of techniques to achieve hemostasis in endoscopic sinus surgery. Int Forum Allergy Rhinol 3(6):482–487. https://doi.org/10.1002/alr.211267CrossRefPubMed

12.

Kinsella JB, Bradfield JJ, Gourley WK, Calhoun KH, Rassekh CH (1996) Allergic fungal sinusitis. Clin Otolaryngol 21:389–392. https://doi.org/10.1046/j.1365-2273.1996.00807CrossRefPubMed

13.

Rudmik L, Hoy M, Schlosser RJ, Harvey RJ, Welch KC, Lund V, Smith TL (2013) Topical therapies in the management of chronic rhinosinusitis: an evidence-based review with recommendations. Int Forum Allergy Rhinol 3:281–298. https://doi.org/10.1002/alr.21096CrossRefPubMed

14.

Dai Q, Duan C, Liu Q, Yu H (2017) Effect of nebulized budesonide on decreasing the recurrence of allergic fungal rhinosinusitis. Am J Otolaryngol 38(3):321–324. https://doi.org/10.1016/j.amjoto.2017.01.03421CrossRefPubMed

15.

Thamboo A, Manji J, Szeitz A et al (2014) The safety and efficacy of short-term budesonide delivered via mucosal atomization device for chronic rhinosinusitis without nasal polyposis. Int Forum Allergy Rhinol 4:397–402. https://doi.org/10.1002/alr.2128022CrossRefPubMed

16.

Manji J, Singh G, Okpaleke C et al (2017) Safety of long-term intranasal budesonide delivered via the mucosal atomization device for chronic rhinosinusitis. Int Forum Allergy Rhinol 7(5):488–493. https://doi.org/10.1002/alr.2191023CrossRefPubMed

17.

Frigas E (2007) A pilot, prospective, double blind, placebo-controlled treatment trial with itraconazole orally in patients with chronic rhinosinusitis and asthma. J Allergy Clin Immunol 119:S142. https://doi.org/10.1016/j.jaci.2006.11.685CrossRef

18.

Kennedy DW, Kuhn FA, Hamilos DL et al (2005) Treatment of chronic rhinosinusitis with high-dose oral terbinafine: a double blind, placebo controlled study. Laryngoscope 115:1793–1799. https://doi.org/10.1097/01.mlg.0000175683.81260CrossRefPubMed

19.

Liang J, Lane AP (2013) Topical drug delivery for chronic rhinosinusitis. Curr Otorhinolaryngol Rep 1(1):51–60. https://doi.org/10.1007/s40136-012-0003-4CrossRefPubMed

20.

Mabry RL, Mabry CS (2000) Allergic fungal sinusitis the role of immunotherapy. Otolaryngol Clin N Am 33:433–440CrossRef

21.

Folker RJ, Marple BF, Mabry RL, Mabry CS (1998) Treatment of allergic fungal sinusitis: a comparison trial of postoperative immunotherapy with specific fungal antigens. Laryngoscope 108:1623–1627CrossRefPubMed

22.

Quinn JM, Wickern GM, Whisman BA et al (1995) Immunotherapy in allergic bipolaris sinusitis: a case report. J Allergy Clin Immunol 95:201

23.

Bassichis BA, Marple BF, Mabry RL et al (2001) Use of immunotherapy in previously treated patients with allergic fungal sinusitis. Otolaryngol Head Neck Surg 125:487–490. https://doi.org/10.1067/mhn.2001.119585CrossRefPubMed

24.

Greenhaw B, deShazo RD, Arnold J, Wright L (2011) Fungal immunotherapy in patients with allergic fungal sinusitis. Ann Allergy Asthma Immunol 107:432–436. https://doi.org/10.1016/j.anai.2011.05.021CrossRefPubMed

25.

Ferguson BJ (1993) Lmmunotherapy and antifungal therapy in allergic fungal sinusitis. Paper presented at: 1993 annual meeting of the American Academy of Otolaryngic Allergy, Minneapolis

26.

Novartis.ca [Internet] (2017) Product monograph: pr XOLAIR® (omalizumab). Published 2017. Available from: https://www.novartis.com/ca-en/sites/novartis_ca/files/clozaril_scrip_e.pdf. Accessed 14 August 2020

27.

Kim H, Ellis AK, Fischer D et al (2017) Asthma biomarkers in the age of biologics. Allergy Asthma Clin Immunol 13:48. https://doi.org/10.1186/s13223-017-0219-4CrossRefPubMedPubMedCentral

28.

Gan EC, Habib AR, Rajwani A, Javer AR (2015) Omalizumab therapy for refractory allergic fungal rhinosinusitis patients with moderate or severe asthma. Am J Otolaryngol 36(5):672–677. https://doi.org/10.1016/j.amjoto.2015.05.008CrossRefPubMed

29.

Corren J, Castro M, O’Riordan T et al (2020) Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol Pract 8(2):516–526CrossRefPubMed

30.

Beck LA, Thaçi D, Hamilton JD et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371(2):130–139CrossRefPubMed

31.

Bachert C, Han JK, Desrosiers M et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS- 52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394(10209):1638–1650CrossRefPubMed

32.

Lo RM, Liu AY, Valdez TA, Gernez Y (2020) Dupilumab use in recalcitrant allergic fungal rhinosinusitis. Ann Allergy Asthma Immunol 125(5):617–619CrossRefPubMed

33.

Alotaibi NH, Aljasser LA, Arnaout RK, Alsomaili S (2021) A case report of allergic fungal rhinosinusitis managed with Dupilumab. Int J Surg Case Rep 88:106479CrossRefPubMedPubMedCentral

34.

Bulkhi AA, Mirza AA, Aburiziza AJ, Marglani OA (2022) Dupilumab: an emerging therapy in allergic fungal rhinosinusitis. World Allergy Organ J 15:100638CrossRefPubMedPubMedCentral

35.

Iqbal IZ, Kao SS, Ooi EH (2020) The role of biologics in chronic rhinosinusitis: a systematic review. Int Forum Allergy Rhinol 10(2):165–174CrossRefPubMed

36.

Bachert C, Hellings PW, Mullol J et al (2020) Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy 75(1):148–157CrossRefPubMed

37.

White JW, Subers MH, Schepartz AI (1963) The identification of inhibine, the antibacterial factor in honey, as hydrogen peroxide and its origin in a honey glucose-oxidase system. Biochim Biophys Acta 73:57–70. https://doi.org/10.1016/0926-6569(63)90108-1CrossRefPubMed

38.

Blair SE, Cokcetin NN, Harry EJ et al (2009) The unusual antibacterial activity of medical-grade Leptospermum honey: antibacterial spectrum, resistance and transcriptome analysis. Eur J Clin Microbiol Infect Dis 28:1199–1208. https://doi.org/10.1007/s10096-009-0763-zCrossRefPubMed

39.

Mavric E, Wittmann S, Barth G et al (2008) Identification and quantification of methylglyoxal as the dominant antibacterial constituent of Manuka (Leptospermum scoparium) honeys from New Zealand. Mol Nutr Food Res 52:483–489. https://doi.org/10.1002/mnfr.200700282CrossRefPubMed

40.

Yabes JM, White BK, Murray CK et al (2017) In vitro activity of Manuka honey and polyhexamethylene biguanide on filamentous fungi and toxicity to human cell lines. Med Mycol 55(3):334–343. https://doi.org/10.1093/mmy/myw070CrossRefPubMed

41.

Irish J, Carter DA, Shokohi T, Blair SE (2006) Honey has an antifungal effect against Candida species. Med Mycol 44(3):289–291. https://doi.org/10.1080/13693780500417037CrossRefPubMed

42.

Thamboo A, Thamboo A, Philpott CM, Javer AR, Clark A (2011) Single- blind study of manuka honey in allergic fungal rhinosinusitis. J Otolaryngol Head Neck Surg 40(3):238–243PubMed

43.

Brave New (Microbial) World: implications for nasal and sinus disorders. Martin DesrosiersFabiana Cardoso Pereira Valera

44.

Stephenson MF, Mfuna L, Dowd SE, Wolcott RD, Barbeau J, Poisson M et al (2010) Molecular characterization of the polymicrobial flora in chronic rhinosinusitis. J Otolaryngol Head Neck Surg 39:182–187PubMed

45.

Mahdavinia M, Keshavarzian A, Tobin MC, Landay AL, Schleimer RP (2016) A comprehensive review of the nasal microbiome in chronic rhinosinusitis (CRS). Clin Exp Allergy 46:21–41CrossRefPubMedPubMedCentral

46.

Cleland EJ, Drilling A, Bassiouni A, James C, Vreugde S, Wormald PJ (2014) Probiotic manipulation of the chronic rhinosinusitis microbiome. Int Forum Allergy Rhinol 4:309–314CrossRefPubMed

47.

Cope EK, Lynch SV (2015) Novel microbiome-based therapeutics for chronic rhinosinusitis. Curr Allergy Asthma Rep 15:504CrossRefPubMed

48.

Tapiovaara L, Pitkaranta A, Korpela R (2016) Probiotics and the upper respiratory tract—a review. Pediatric Infect Dis 1:19CrossRef

49.

Abreu NA, Nagalingam NA, Song Y, Roediger FC, Pletcher SD, Goldberg AN et al (2012) Sinus microbiome diversity depletion and Corynebacterium tuberculostearicum enrichment mediates rhinosinusitis. Sci Transl Med 4:151ra124CrossRefPubMedPubMedCentral

50.

Mårtensson A, Greiff L, Lamei SS, Lindstedt M, Olofsson TC, Vasquez A et al (2016) Effects of a honeybee lactic acid bacterial microbiome on human nasal symptoms, commensals, and biomarkers. Int Forum Allergy Rhinol 6:956–963CrossRefPubMed

51.

Mårtensson A, Abolhalaj M, Lindstedt M, Mårtensson A, Olofsson TC, Vásquez A et al (2017) Clinical efficacy of a topical lactic acid bacterial microbiome in chronic rhinosinusitis: a randomized controlled trial. Laryngoscope Investig Otolaryngol 2:410–416CrossRefPubMedPubMedCentral

52.

Alromaih S, Mfuna Endam L, Desrosiers M, Cousineau B, Madrenas J (2016) Self administered topical probiotic is beneficial for refractory CRS. Otolaryngol Head Neck Surg 155:P144–P156

53.

Biel MA, Sievert C, Usacheva M, Teichert M, Balcom J (2011) Antimicrobial photodynamic therapy treatment of chronic recurrent sinusitis biofilms. Int Forum Allergy Rhinol 1(5):329–334. https://doi.org/10.1002/alr.2008958CrossRefPubMedPubMedCentral

54.

Romo C, Loebel N, Meller D, Andersen R (2019) A pilot study of antimicrobial photodynamic therapy of encapsulated Aspergillus fumigatus in a rabbit maxillary sinus model. In: 17th International photodynamic association world congress, p 110708J

55.

Bigliardi PL, Alsagoff SAL, El-Kafrawi HY, Pyon JK, Wa CTC, Villa MA (2017) Povidone iodine in wound healing: a review of current concepts and practices. Int J Surg 44:260–268. https://doi.org/10.1016/j.ijsu.2017.06.073CrossRefPubMed

56.

Beukelman CJ, van den Berg AJ, Hoekstra MJ, Uhl R, Reimer K, Mueller S (2008) Anti-inflammatory properties of a liposomal hydrogel with povidone-iodine (Repithel) for wound healing in vitro. Burns 34:845–855. https://doi.org/10.1016/j.burns.2007.11.014CrossRefPubMed

57.

Al-Kaisy AA, Salih Sahib A (2005) Role of the antioxidant effect of vitamin E with vitamin C and topical povidone-iodine ointment in the treatment of burns. Ann Burns Fire Disasters 18:19–30PubMedPubMedCentral

58.

Vehmeyer-Heeman M, Van den Kerckhove E, Gorissen K, Boeckx W (2005) Povidone-iodine ointment: no effect of split skin graft healing time. Burns 31:489–494. https://doi.org/10.1016/j.burns.2004.11.018CrossRefPubMed

59.

Mullings W, Panchmatia R, Samoy K et al (2019) Topical povidone-iodine as an adjunctive treatment for recalcitrant chronic rhinosinusitis. Eur J Rhinol Allergy 2(2):45–50. https://doi.org/10.5152/ejra.2019.166CrossRef

60.

Panchmatia R, Payandeh J, Al-Salman R et al (2019) The efficacy of diluted topical povidone-iodine rinses in the management of recalcitrant chronic rhinosinusitis: a prospective cohort study. Eur Arch Otorhinolaryngol 276(12):3373–3381. https://doi.org/10.1007/s00405-019-05628-wCrossRefPubMed

61.

Kim J, Rimmer J, Mrad N, Ahmadzada S (2014) Betadine has a ciliotoxic effect on ciliated human respiratory cells. J Laryngol Otol 129:1–6. https://doi.org/10.1017/S002221511400274666CrossRef

62.

Averyanov AA, Lapikova VP, Pasechnik TD, Kuznetsov VV, Jacyn Baker C (2007) Suppression of early stages of fungus development by hydrogen peroxide at low concentrations. Plant Pathol J 6:242–247. https://doi.org/10.3923/ppj.2007.242.247CrossRef

63.

Blaine DA, Frable MA (1996) Mucormycosis. Adjunctive therapy with hydrogen peroxide. Va Med Q 123(1):30–32PubMed

64.

Larsen B, White S (1995) Antifungal effect of hydrogen peroxide on catalase-producing strains of Candida spp. Infect Dis Obstet Gynecol 3(2):73–78. https://doi.org/10.1155/S1064744995000354CrossRefPubMedPubMedCentral

Title: Emerging Therapies in the Medical Management of Allergic Fungal Rhinosinusitis
Authors: Osama A. Marglani
Rehab F. Simsim
Publication date: 12-09-2023
Publisher: Springer India
Keywords: Rhinosinusitis
Dupilumab
Budesonide
Published in: Indian Journal of Otolaryngology and Head & Neck Surgery / Issue 1/2024
Print ISSN: 2231-3796
Electronic ISSN: 0973-7707
DOI: https://doi.org/10.1007/s12070-023-04143-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Emerging Therapies in the Medical Management of Allergic Fungal Rhinosinusitis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Xanthogranuloma in the External Auditory Canal in Childhood, an Unexpected Lesion

A Prospective Randomized Controlled Trial Comparing the Psychological Impact of Traditional Cold Steel Adenoidectomy and Endoscopic-Assisted Cold Steel Adenoidectomy

The Evolution of Foreign Bodies Management in a Case of Near-fatal Penetrating Neck Injury

Diffuse Large B Cell Lymphoma of Lacrimal Drainage System : A Rare Case Report

Outcomes of Central Neck Dissection for Papillary Thyroid Carcinoma in Primary Versus Revision Setting

Exponential Rise of Fungal Infection Reported in Rajkot Civil Hospital in Covid Pandemic Era: A Retrospective Study